Agomelatin: Yeni Antidepresan İlaç ve Yeni Bulgular
Makaleler > Tam Makale · 2012
Yazarlar: Fisun Akdeniz
DergiPark (Istanbul University), Uluslararası, 2012, cilt 2
DOI: 10.5455/jmood.20120924064532
Özet
Agomelatine is a novel antidepressant drug with melatoninergic (MT1/MT2 receptor agonist) and 5-HT2c receptor antagonist activity. Because of favorable side effect profile, it is associated with good treatment adherence. Agomelatine has demonstrated its antidepressant efficacy in five double-blind placebo controlled short-term studies, an extended to 10 months relapse prevention trial and head-to-head comparative clinical trials (paroxetine, sertraline, fluoxetine, escitalopram, venlafaxine). In the published researches, it is shown that agomelatine is superior to placebo in antidepressant efficacy, comparable to other antidepressants and well tolerated than other antidepressants. The positive effects of agomelatine on anxiety and sleep-wake cycles are remarkable. There were no sexual adverse effects of agomelatine reported in the clinical trials, even it can improve the symptoms of sexual disorder due to major depression. Clinical practice will support the evidence from clinical trials in future.